# Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent

Study · id `cardio:ct-nct05516446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05516446](<https://clinicaltrials.gov/study/NCT05516446>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05516446

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 290 participants.

## Technical summary

Registry record NCT05516446. Randomized; single masking; primary purpose treatment. Start 2021-08-25 (actual); primary completion 2022-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 290 participants (planned count; ClinicalTrials.gov record NCT05516446, source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)
- Started: 2021-08-25 (actual) (ClinicalTrials.gov record NCT05516446, source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)
- Primary completion: 2022-11 (anticipated) (ClinicalTrials.gov record NCT05516446, source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)
- Completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT05516446, source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)
- Countries: Tunisia (ClinicalTrials.gov record NCT05516446, source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05516446-2022-08-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Drug Eluting Balloon Angioplasty Versus Everolimus Platinum Chrome Stent
- Acronym: DEBATE
- Condition: Percutaneous Coronary Intervention (PCI)
- Condition: Coronary Artery Disease (CAD)
- Condition: De Novo Stenosis
- Intervention (Device): DEB for de Novo Lesions
- Intervention (Device): DES for de Novo Lesions
- Lead sponsor: General Administration of Military Health, Tunisia
- Lead sponsor class: NETWORK
- Collaborator: B. Braun Medical International Trading Company Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: B. Braun Medical International Trading Company Ltd. (`cardio:org-b-braun-medical-international-trading-company-ltd`)

## Provenance

Content hash: ca8ada337ee8859251210716cca07416558a95feb253df1696f65d4ef46aa59d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
